JP2005526040A - 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用 - Google Patents

失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用 Download PDF

Info

Publication number
JP2005526040A
JP2005526040A JP2003569190A JP2003569190A JP2005526040A JP 2005526040 A JP2005526040 A JP 2005526040A JP 2003569190 A JP2003569190 A JP 2003569190A JP 2003569190 A JP2003569190 A JP 2003569190A JP 2005526040 A JP2005526040 A JP 2005526040A
Authority
JP
Japan
Prior art keywords
cyclooxygenase
incontinence
inhibitor
chloride
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003569190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526040A5 (enExample
Inventor
エブラヒム・ヴァーシ
Original Assignee
ファルマシア・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア・コーポレーション filed Critical ファルマシア・コーポレーション
Publication of JP2005526040A publication Critical patent/JP2005526040A/ja
Publication of JP2005526040A5 publication Critical patent/JP2005526040A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003569190A 2002-02-19 2003-02-14 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用 Abandoned JP2005526040A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35788802P 2002-02-19 2002-02-19
PCT/US2003/004561 WO2003070233A1 (en) 2002-02-19 2003-02-14 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Publications (2)

Publication Number Publication Date
JP2005526040A true JP2005526040A (ja) 2005-09-02
JP2005526040A5 JP2005526040A5 (enExample) 2006-03-30

Family

ID=27757670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569190A Abandoned JP2005526040A (ja) 2002-02-19 2003-02-14 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用

Country Status (12)

Country Link
US (1) US20030191172A1 (enExample)
EP (1) EP1476146A1 (enExample)
JP (1) JP2005526040A (enExample)
KR (1) KR20050005410A (enExample)
CN (1) CN1633283A (enExample)
AU (1) AU2003211078A1 (enExample)
BR (1) BR0307772A (enExample)
CA (1) CA2475374A1 (enExample)
MX (1) MXPA04008037A (enExample)
PL (1) PL372395A1 (enExample)
WO (1) WO2003070233A1 (enExample)
ZA (1) ZA200406148B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506359A (ja) * 2012-01-04 2015-03-02 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための遅延放出製剤およびその使用の方法
JP2015510928A (ja) * 2012-03-19 2015-04-13 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための延長放出製剤およびその使用方法
WO2019244937A1 (ja) * 2018-06-20 2019-12-26 花王株式会社 ロズマリン酸誘導体又はその塩
JP2020033272A (ja) * 2018-08-27 2020-03-05 花王株式会社 過活動膀胱の予防又は改善剤
WO2020075764A1 (ja) * 2018-10-10 2020-04-16 花王株式会社 Ｔｒｐｖ４活性抑制剤

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
WO2005011683A1 (ja) * 2003-08-04 2005-02-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
AU2005226357B2 (en) * 2004-03-25 2010-07-01 Astellas Pharma Inc. Composition for solid pharmaceutical preparation of solifenacin or salt thereof
JP4895819B2 (ja) * 2004-10-29 2012-03-14 大鵬薬品工業株式会社 プロピベリン含有経口粉粒状製剤及びその製造法
WO2006082888A1 (ja) * 2005-02-03 2006-08-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PT2125021E (pt) * 2006-12-22 2011-07-26 Recordati Ireland Ltd Terapia de combinação de distúrbios do tracto urinário inferior com 2 ligandos e nsaid
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US8236857B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120237574A1 (en) * 2010-07-08 2012-09-20 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
CN103191429A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
EP2612663A1 (en) * 2012-01-04 2013-07-10 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
EP2612660B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
CN103191430A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的缓释制剂及其使用方法
EP2612662B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Delayed-release formulation for reducing the frequency of urination and method of use thereof
BR112014016661A8 (pt) 2012-01-04 2017-07-04 Wellesley Pharmaceuticals Llc formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
TWI587879B (zh) * 2012-01-04 2017-06-21 魏斯理製藥公司 用於減少排尿頻率的延長釋放製劑及其使用方法
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
CA2875818A1 (en) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
RU2016152226A (ru) * 2014-06-06 2018-07-09 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
CN110279863B (zh) * 2019-07-29 2022-02-22 牡丹江医学院 用于治疗泌尿疾病的药物组合物及其制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506359A (ja) * 2012-01-04 2015-03-02 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための遅延放出製剤およびその使用の方法
JP2017122091A (ja) * 2012-01-04 2017-07-13 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための遅延放出製剤およびその使用の方法
JP2015510928A (ja) * 2012-03-19 2015-04-13 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための延長放出製剤およびその使用方法
WO2019244937A1 (ja) * 2018-06-20 2019-12-26 花王株式会社 ロズマリン酸誘導体又はその塩
JP2019218308A (ja) * 2018-06-20 2019-12-26 花王株式会社 ロズマリン酸誘導体又はその塩
JP7195067B2 (ja) 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩
JP2020033272A (ja) * 2018-08-27 2020-03-05 花王株式会社 過活動膀胱の予防又は改善剤
WO2020075764A1 (ja) * 2018-10-10 2020-04-16 花王株式会社 Ｔｒｐｖ４活性抑制剤
JP2020059675A (ja) * 2018-10-10 2020-04-16 花王株式会社 Ｔｒｐｖ４活性抑制剤
JP7223477B2 (ja) 2018-10-10 2023-02-16 花王株式会社 Ｔｒｐｖ４活性抑制剤

Also Published As

Publication number Publication date
CA2475374A1 (en) 2003-08-28
US20030191172A1 (en) 2003-10-09
MXPA04008037A (es) 2004-11-26
ZA200406148B (en) 2006-05-31
BR0307772A (pt) 2004-12-07
CN1633283A (zh) 2005-06-29
KR20050005410A (ko) 2005-01-13
WO2003070233A1 (en) 2003-08-28
AU2003211078A1 (en) 2003-09-09
PL372395A1 (en) 2005-07-25
EP1476146A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
JP2005526040A (ja) 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用
US10874644B2 (en) Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function
CN102065898B (zh) 通过调节血管发生治疗阿茨海默病和相关病症的新治疗手段
CA2415577C (en) Use of cox-2 inhibitors for preventing immunodeficiency
JP2004521123A (ja) 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
JPWO2004093910A1 (ja) ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
JP2010522139A (ja) α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
US20040121961A1 (en) Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
WO2005020926A2 (en) Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
US20050187278A1 (en) Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
JP5579958B2 (ja) Ｃｏｘ−２インヒビターを含有する鎮痛及び抗炎症性組成物
US20090312311A1 (en) Combination of organic compounds
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
ES2281775T3 (es) Metodo para tratar insuficiencia renal.
EP1915992A1 (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
HK1073795A (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
AU2015203036A1 (en) Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
AU2001270902B2 (en) Use of COX-2 inhibitors for preventing immunodeficiency
AU6590498A (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
HK1059378B (en) Analgesic and anti-inflammatory compositions containing cox-2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060209

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20080606